Introduction {#s1}
============

Alzheimer's disease (AD) is one of the most widespread types of irreversible dementia among the older population. It is clinically characterized by a progressive cognitive decline (e.g. memory loss, difficulties in learning new tasks, problems with attention and orientation), behavioral changes (e.g. anxiety, depression, and sleep--wake cycle alterations), and inability to maintain activities of daily living ([@B68]; [@B6]).

The early-onset form of AD (age \< 65 years) is distinguished by a rapid progression and is linked to the dominant mutations in amyloid precursor protein (APP) and presenilin proteins 1 and 2 (PS 1 and PS2). Mutation in the apolipoprotein E (ApoE) gen, is related to the sporadic late-onset variation of AD (age \> 65 years). This form, present in the majority of AD population, is considered multifactorial, since both genetic predisposition and several other factors contribute to the progression of the disease. Excepting aging as the major determinant, other risk factors are more modifiable including lifestyle habits (mental, physical, and social activities, smoking, nutrition), cardiovascular risk factors (obesity, diabetes mellitus, hypertension, etc.), and head injury ([@B44]).

The main AD neuropathological features are the presence of extracellular amyloid deposits (senile plaques) in the brain parenchyma and cerebral blood vessels as well as intracellular neurofibrillary tangles accumulation ([@B66]; [@B20]). Amyloid deposits are composed of abnormally folded amyloid β (Aβ) peptides with 40 or 42 amino acids, produced by sequential cleavage of the transmembrane APP, *via* β and ƴ-secretase enzymes. Intracellular neurofibrillary tangles are formed by an accumulation of hyperphosphorylated and misfolded tau protein. The neuropathological hallmarks are accompanied by extensive microglia cells and astrocyte activation, the key event in neuroinflammation ([@B72]; [@B28]; [@B97]; [@B41]; [@B49]). These cells produce cytokines (interleukins (ILs), tumor necrosis factors (TNFs), transforming growth factors (TGFs), and interferons (IFN). In AD, some of them have pro-inflammatory (IL-1β, TNFα, and IFN-γ), anti-inflammatory (IL-4, IL-10, and TGF-β) or even both properties (IL-6) ([@B71]; [@B32]).

Both Aβ peptides and PS are implicated in the intracellular Ca^2+^ dyshomeostasis ([@B47]; [@B11]; [@B24]; [@B4]; [@B88]). The Aβ peptides produce an excessive elevation in intracellular Ca^2+^ through the formation of Ca^2+^-permeable pores in the plasma membrane or increasing Ca^2+^ influx *via* activation of L-type Ca^2+^ channels and N-methyl-[d]{.smallcaps}-aspartate (NMDA) receptors. Mutated PSs may form passive Ca^2+^-leak channels on the endoplasmic reticulum, and together with enhanced ryanodine and inositol 1,4,5-trisphosphate receptors function, augment Ca^2+^ level in the cytoplasm and mitochondria ([@B139]). The dysregulation of cellular Ca^2+^ homeostasis in aging and AD leads to mitochondrial dysfunction, increased production of reactive oxygen species, autophagy, impaired synaptic plasticity, reduced long-term potentiation (LTP), enhanced long-term depression, synaptic loss, cell death, and eventually cognitive decline ([@B25]; [@B57]; [@B132]; [@B78]; [@B127]; [@B89]; [@B63]). Therefore, targeting the disturbed calcium homeostasis is one plausible option for the prevention and therapy of AD.

Verapamil (C~27~H~38~N~2~O~4~), a generic name for iproveratril, which was discovered in the mid-1960s, belongs to the first generation of the phenylalkylamine class of calcium channel antagonists ([@B29]; [@B79]), and it is commercialized as a racemic mixture of levo (S) and dextro (R) enantiomers. Verapamil causes dilatation of the main coronary and systemic arteries and decreases myocardial contractility ([@B29]; [@B79]). Therefore, for many years it has been deployed as a treatment option for cardiovascular diseases, such as hypertension ([@B61]; [@B76]), supraventricular tachyarrhythmias ([@B110]; [@B52]), and angina pectoris ([@B65]; [@B86]). Remarkably, verapamil has been also used as a drug option for the treatment of hypertrophic and keloid scars ([@B3]; [@B136]), obesity-associated autophagy defects and fatty liver pathologies ([@B85]), osteoarthritis ([@B69]), cluster headache ([@B75]; [@B131]; [@B60]; [@B90]), bipolar disorders ([@B142]; [@B18]; [@B27]), type 2 diabetes ([@B146]; [@B16]; [@B15]), chronic rhinosinusitis ([@B77]), Peyronie's disease ([@B107]), tuberculosis ([@B104]; [@B123]), epilepsy ([@B80]; [@B133]), and reversible cerebral vasoconstriction syndrome ([@B14]). However, verapamil has expressed ambiguous effects in Parkinson's disease ([@B34]; [@B87]) and dementia ([@B70]; [@B145]; [@B81]).

The aim of this mini review is to bring together data about the potential effects of verapamil on the prevention and therapy of AD, and highlights some concerns for future research.

Alzheimer's Disease And Verapamil {#s2}
=================================

Experimental Findings {#s2_1}
---------------------

### *Ex Vivo* Studies {#s2_1_1}

It has been demonstrated that verapamil ameliorated the neurotoxicity caused by Aβ and reduces the Aβ~1--40~ oligomer levels by improving their efflux from the LS-180 cells, *via* P-glycoprotein up-regulation ([@B1]). Verapamil also restores the microtubule-binding activity of tau and ameliorates the level of oxidative stress in the SH-SY5Y neuroblastoma cell line exposed to Aβ~1--42~ ([@B74]). Physiological studies indicated that the Aβ~25--35~-induced depression of LTP in a hippocampal slice preparation may be attenuated by verapamil ([@B31]). Furthermore, this drug protected MC65 neuroblastoma cells from the APP C-terminal fragment-induced neurotoxicity ([@B5]). However, [@B141] demonstrated the inefficiency of verapamil in the prevention of Aβ~1--40~ neurotoxicity in a pure hippocampal neuronal culture, suggesting that glial-neuronal interaction is important for the preventive effect of verapamil. The rise of Ca^2+^ concentration was inhibited by verapamil in a human microglia cells culture treated with Aβ~25--35~ ([@B118]).

Verapamil pre-treatment protects IMR-32 cells against the scopolamine-induced cytotoxicity, attenuates oxidative stress, and prevents mitochondrial damage ([@B91]). It also augments the expression of genes involved in the cholinergic function (mACR1), Ca^2+^-dependent memory-related genes (CREB1, CREBBP, BDNF), and synaptic plasticity (GAP43, SYP) that were downregulated by scopolamine ([@B91]). Nevertheless, the lipopolysaccharide neurotoxicity in mesencephalic dopaminergic neurons that are dependent on microglia activation and augmented production of pro-inflammatory factors (superoxide, NO, and TNF-α) may be abolished by verapamil treatment ([@B64]). Similarly, verapamil significantly reduces IFN-γ;-induced neurotoxicity of human astrocytes to SH-SY5Y neuroblastoma cells ([@B40]). Moreover, both R and S-isomers of verapamil show equivalent potency to reduce the microglia-mediated neurotoxicity, even though the R-isomer has much less activity to block L-type calcium channels than the S counterpart ([@B64]).

### *In Vivo* Studies {#s2_1_2}

###### 

Effect of verapamil (V) on learning and memory in three animal models of Alzheimer's disease (AD): nucleus basalis magnocellularis (NBM) lesion, scopolamine (S) treatment, and intracerebroventricular injection (icv) of streptozotocin (STZ).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AD model/reference                                                                Experimental animal         Treatment        Active avoidance                                                                                   Elevated plus maze---retention   Passive avoidance---retention   Novel object recognition---retention   Morris water maze                                   
  --------------------------------------------------------------------------------- --------------------------- ---------------- -------------------------------------------------------------------------------------------------- -------------------------------- ------------------------------- -------------------------------------- ------------------- --------------- --------------- --------------
  NBM-lesion/[@B94]                                                                 Wistar rats\                Saline\          s.c., 30 min before test. Test performed 10 days after lesion.                                     ↓\                               ↓\                                                                                                                         
                                                                                    Young adult ♂               V 1\                                                                                                                ns\                              ns\                                                                                                                        
                                                                                                                V 2.5\                                                                                                              *p* \< 0.05↑\                    *p* \< 0.05↑\                                                                                                              
                                                                                                                V 5\                                                                                                                *p* \< 0.01↑\                    *p* \< 0.01↑\                                                                                                              
                                                                                                                V 10                                                                                                                ns                               ns                                                                                                                         

  NBM-lesion/[@B96]                                                                 Wistar rats\                Saline\          i.p., 24 h after lesion in duration of 8 days (every 12 h). Test performed 13 days after lesion.                                    ↓\                                                                                                                         
                                                                                    Young adult ♂               V 1\                                                                                                                                                 ns\                                                                                                                        
                                                                                                                V 2.5\                                                                                                                                               *p* \< 0.05↑\                                                                                                              
                                                                                                                V 5\                                                                                                                                                 *p* \< 0.01↑\                                                                                                              
                                                                                                                V 10                                                                                                                                                 ns                                                                                                                         

  Scopolamine, 3 mg/kg i.p./[@B91]                                                  Swiss mice Young adult ♂    S 3\             \                                                                                                                                                                   ↓\                                     ↓\                                                  
                                                                                                                S 3+V 5\         i.p., 7 days, last V dose 60 min before S and 90 min before test                                                                                                    ns\                                    p \< 0.05↑\                                         
                                                                                                                S 3+V 10                                                                                                                                                                             p \< 0.05↑                             p \< 0.05↑                                          

  Scopolamine: 0.9 mg/kg i.p., 7 days/[@B115]                                       Wistar rats Young adult ♀   S 0.9\           \                                                                                                                                                                   ↓\                                                         ↓\                              
                                                                                                                \                p.o., 7 days, V 30 min:\                                                                                                                                            \                                                          \                               
                                                                                                                \                -- before S\                                                                                                                                                        \                                                          \                               
                                                                                                                V 21.6\          -- after S                                                                                                                                                          *p* \< 0.05↑\                                              *p* \< 0.05↑\                   
                                                                                                                V 21.6                                                                                                                                                                               *p* \< 0.01↑                                               *p* \< 0.05↑                    

  Scopolamine: i.p., 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 1 mg/kg, 3 mg/kg/[@B147]   C57BL/6J mice\              S 0.025\         \                                                                                                                                                                                                                              ns\                             
                                                                                    Young adult ♂               S 0.05\          \                                                                                                                                                                                                                              ns\                             
                                                                                                                S 0.1\           \                                                                                                                                                                                                                              ns\                             
                                                                                                                S 1\             \                                                                                                                                                                                                                              ↓\                              
                                                                                                                S 3\             \                                                                                                                                                                                                                              ↓\                              
                                                                                                                S 0.025 + V 5\   i.p., V 60 min before S                                                                                                                                                                                                        ns\                             
                                                                                                                S 1 + V 5\                                                                                                                                                                                                                                      \                               
                                                                                                                S 3 + V 5                                                                                                                                                                                                                                       ns\                             
                                                                                                                                                                                                                                                                                                                                                                ns                              

  icv-STZ/[@B54]                                                                    Wistar rats Young adult ♂   icv-STZ\         \                                                                                                                                                                   ↓\                                                                         ↓\              ↓\
                                                                                                                V 2.5\           i.p. 21 days\                                                                                                                                                       *p* \< 0.05↑\                                                              *p* \< 0.05↑\   ns\
                                                                                                                V 5              i.p. 21 days                                                                                                                                                        *p* \< 0.05↑                                                               *p* \< 0.05↑    *p* \< 0.05↑
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

s.c., subcutaneous; i.p., intraperitoneal; p.o., oral.

↑ cognitive improvement; ↓ cognitive impairment.

###### 

Effect of verapamil (V) on anxiety-like behavior (open field and elevated plus maze tests), depressive-like behavior (learned helplessness, forced swimming and novelty suppressed tests) and aggression (foot-shock aggression) in two animal models of Alzheimer's disease (AD): nucleus basalis magnocellularis (NBM) lesion and scopolamine (S).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AD model/reference                                                                Experimental animal        Treatment        Open field                                                                     Elevated plus maze   Learned helplessness   Forced swimming test   Novelty suppressed feeding   Foot-shock aggression                                                   
  --------------------------------------------------------------------------------- -------------------------- ---------------- ------------------------------------------------------------------------------ -------------------- ---------------------- ---------------------- ---------------------------- ----------------------- ---------------- --------------- -------------- -----
  NBM-lesion/[@B95]                                                                 Wistar rats\               Saline\          s.c., 30 min before test. Test performed 10 days after lesion.                 ↑\                   ns\                    ↑\                     ↓\                                                                                                   
                                                                                    Young adult ♂              V 1\                                                                                            ns\                  ns\                    ns\                    ns\                                                                                                  
                                                                                                               V 2.5\                                                                                          *p* \< 0.001↓\       ns\                    *p* \< 0.001↓\         *p* \< 0.05↑\                                                                                        
                                                                                                               V 5\                                                                                            *p* \< 0.01↓\        ns\                    *p* \< 0.01↓\          ns\                                                                                                  
                                                                                                               V 10                                                                                            ns                   ns                     ns                     ns                                                                                                   

  NBM-lesion/[@B96]                                                                 Wistar rats\               Saline\          i.p., 24h after lesion in duration of 8 days (every 12h). Test performed 13\   ↑\                   ns\                    ↑\                     ↓\                                                   ↓\                                              ↓\
                                                                                    Young adult ♂              V 1\             days after lesion.                                                             ns\                  ns\                    ns\                    ns\                                                  ns\                                             ns\
                                                                                                               V 2.5\                                                                                          *p* \< 0.001↓\       ns\                    *p* \< 0.01↓\          *p* \< 0.001↑\                                       *p* \< 0.05↑\                                   ns\
                                                                                                               V 5\                                                                                            *p* \< 0.001↓\       ns\                    *p* \< 0.001↓\         *p* \< 0.01↑\                                        *p* \< 0.001↑\                                  ns\
                                                                                                               V 10                                                                                            ns                   ns                     ns                     ns                                                   ns                                              ns

  NBM lesion/[@B96]                                                                 Wistar rats\               Saline\          s.c., 30 min before test. Test performed 10 days after lesion.                                                                                                                                         ↓\                                              ↓\
                                                                                    Young adult ♂              V 1\                                                                                                                                                                                                                    ns\                                             ns\
                                                                                                               V2.5\                                                                                                                                                                                                                   *p* \< 0.05↑\                                   ns\
                                                                                                               V 5\                                                                                                                                                                                                                    *p* \< 0.05↑\                                   ns\
                                                                                                               V 10                                                                                                                                                                                                                    ns                                              ns

  Scopolamine: 3 mg/kg i.p./[@B91]                                                  Swiss mice Young adult ♂   S 3\             \                                                                                                                                                                              ↑\                                                                      
                                                                                                               S 3+V 5\         i.p.,7 days, last V dose 60 min before S and 90 min before test                                                                                                                ns\                                                                     
                                                                                                               S 3+V 10                                                                                                                                                                                        *p* \< 0.05↓                                                            

  Scopolamine: 0.025 mg/kg i.p./[@B35]                                              Sprague-Dawley rats\       S 0.025\         3 doses every other day i.p.\                                                                                                                                                                                           ↓\              ↓\             
                                                                                    Young adult ♂              \                i.p, V 30 min before S                                                                                                                                                                                                  \               \              
                                                                                                               S 0.025+V 10                                                                                                                                                                                                                             *p* \< 0.05↑    *p* \< 0.05↑   

  Scopolamine: i.p., 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 1 mg/kg, 3 mg/kg/[@B147]   C57BL/6J mice\             S 0.025\         \                                                                              ns\                  ns\                                                                                                                 ↓\                             
                                                                                    Young adult ♂              S 0.05\          \                                                                              ns\                  ns\                                                                                                                 ↓\                             
                                                                                                               S 0.1\           \                                                                              ns\                  ns\                                                                                                                 ns\                            
                                                                                                               S 1\             \                                                                              ns\                  ns\                                                                                                                 ↑\                             
                                                                                                               S 3\             \                                                                              ns\                  ns\                                                                                                                 ↑\                             
                                                                                                               S 0.025 + V 5\   i.p., V 60 min before S                                                        ns\                  ns\                                                                                                                 *p* \< 0.05↑\                  
                                                                                                               S 1 + V 5\                                                                                      \                    \                                                                                                                   \                              
                                                                                                               S 3 + V 5                                                                                       ns\                  ns\                                                                                                                 ns\                            
                                                                                                                                                                                                               ns                   ns                                                                                                                  ns                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

↑ increase values of measured behavioral parameters; ↓ decrease values of measured behavioral parameters.

Nucleus basalis of Meynert (in non-human animals correspond to the nucleus basalis magnocellularis-NBM) is composed of numerous cholinergic neurons that are affected in AD ([@B140]; [@B106]). Therefore, the lesion of this area was taken as an animal model of AD. Studies from our group with rats supported that verapamil, given in doses of 2.5 and 5 mg/kg, ameliorated the effect of NBM electrolytic lesions on learning and memory in active avoidance test ([@B94]), anxiety behavior in open field test ([@B95]), learned helplessness-induced depression ([@B98]), and body temperature ([@B99]). Findings that acute verapamil treatment (5 and 10 mg/kg), in NBM-lesioned rats, abolished cold restraint induced gastric petechiae, while in control rats, it diminished gastric erosion formation, suggest that the verapamil effect may be modified by stress ([@B100]). The long-term treatment with verapamil in NBM-lesioned rats prevented the impairments in active avoidance memory, open field behavior, and performance in learning helplessness tests ([@B96]). Neither acute nor chronic verapamil treatment improved foot-shock induced aggression in NBM-lesioned rats ([@B96]; [@B98], respectively). Moreover, morphological studies indicated that long-term verapamil treatment (2.5, 5, and 10 mg/kg/12 h) produced a significant neuroprotection on NADPH-diaphorase and ChAT-immunopositive cortical neurons in NBM lesioned rats ([@B12]; [@B101]). The above-mentioned studies indicated that verapamil expresses an inverted U-shape mode of action ([**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}).

Systemic administration of scopolamine, a non-selective muscarinic receptor antagonist, has been considered as a pharmacological model of AD ([@B56]; [@B84]; [@B144]). Long-term verapamil treatment, in a dose of 10 mg/kg (but not in a dose of 5 mg/kg), attenuated the increased mouse locomotion induced by scopolamine ([@B91]). However, verapamil in both used doses, improved memory deficit in the elevated plus maze task and passive avoidance test, reversed the increased acetylcholinesterase (AChE) activity, and preserved the mouse brain from the oxidative stress induced by scopolamine ([@B91]). Prophylactic and curative treatment by verapamil significantly abolished scopolamine-induced impairment in both the elevated plus maze test and the novel object recognition task in female rats ([@B115]). The above-mentioned treatment significantly enhanced oxidative stress markers that were decreased by scopolamine and reduced the enhanced AChE level. Furthermore, verapamil, given in a dose of 10 mg/kg, prevented the anti-depressive effect of scopolamine in rats tested in forced swim and novelty suppressed feeding tests. In the same animals, verapamil blocked the scopolamine-induced increase of the brain-derived neurotrophic factor (BDNF)/TrkB activation in the prefrontal cortex ([@B35]). Similarly, verapamil (5 mg/kg) significantly blockaded: 1) the scopolamine antidepressant-like effect, in mice tested in a forced swimming test; and 2) scopolamine upregulated the effect on BDNF and neuropeptide VGF (nonacronymic) content, in the hippocampus and prefrontal cortex ([@B147]). However, verapamil failed to abolish scopolamine-induced amnesia in the novel object recognition test ([@B147]) ([**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}). Our recent study, focused on a passive avoidance task in rats, demonstrated that verapamil, at the dose that *per se* does not affect the memory consolidation, significantly reversed the memory consolidation improvement induced by scopolamine ([@B36]).

Intracerebroventricular injection (icv) of streptozotocin (STZ) has been described as an experimental model for sporadic AD ([@B54]). In this rat model, chronic verapamil treatment (2.5 and 5 mg/kg) significantly improved memory in both the elevated plus maze test and the Morris water maze task ([@B54]). Moreover, at mentioned doses, verapamil attenuated AChE activity in the hippocampus and frontal cortex. However, only the higher verapamil dose attenuated the oxidative stress damage and the level of TNF-α in the hippocampus and frontal cortex of icv-STZ-injected rats ([@B54]) ([**Table 1**](#T1){ref-type="table"}). At the same dose, verapamil significantly reduced number of apoptotic pyramidal cells at the CA3 hippocampal region.

The icv administration of peptide Aβ~25--35~ in adult Wistar rats causes depression of LTP in the hippocampal CA1 area. This depression is significantly reversed by intraperitoneal administration of 1 mg/kg of verapamil, and with less efficacy at 10 mg/kg ([@B31]).

Verapamil (1 mg/kg/day), given orally (drinking water) for 3 months, inhibits Aβ formation and Ser202/Thr205 phosphorylation of tau by blocking the TXNIP/ROS/p38 MAPK pathway in the hippocampus of 5xFAD transgenic mice ([@B74]).

Clinical Findings {#s2_2}
-----------------

Studies on AD patient brains have shown that phenylalkylamines receptor binding parameters, K~D~ (affinity) and B~max~ (density), are not affected in frontal, temporal, parietal, and occipital cortices, hippocampus, striatum, and thalamus ([@B116]), suggesting, altogether, that clinical trials with verapamil should not be impeded by the functionality of these receptors. One limited prospective study indicated that the use of verapamil neither significantly reduced the risk of developing AD nor had an effect on the risk of all-cause mortality ([@B145]).

Particularities of Mechanism of Action of Verapamil: Pros and Cons {#s2_3}
------------------------------------------------------------------

Although initially considered as an L-type Ca^2+^ channel blocker (Cav1.2 and Cav1.3 alpha subunits), verapamil also binds the alpha subunits of P/Q type (Cav2.1), N-type (Cav2.2), R-type (Cav2.3), and T-type (Cav3.1 and Cav3.2) calcium channels ([@B45]; [@B13]; [@B26]; [@B129]; [@B55]). Both Cav1.2 and Cav1.3 alpha subunits are similarly upregulated at the surface level in rat cultured hippocampal neurons exposed to the Aβ~25--35~ ([@B48]). On one hand, a study performed in 2, 4- and 11-month transgenic mice, overexpressing hAβPP751 with the London (V717I) and Swedish (K670M/N671L) mutations, indicated that the expression of Cav1.2 α1-subunits in reactive astrocytes, is related to the increased amyloid-β load in the plaques ([@B23]). On the other hand, a blockade of the Cav3.1 T-type channel reduces non-amyloidogenic processing and produces higher levels of Aβ peptide in the brain of 3xTg-AD mice aged 14 to 16 months ([@B105]). The pathological, aggregated form of Aβ~1--40,~ reduced Ca^2+^ channel current density in cortical neurons, *via* an action on N-type calcium channels ([@B103]), as well as Aβ~1--42~ globulomer inhibited presynaptic P/Q calcium currents in hippocampal cells ([@B82]). These findings pinpointed that verapamil may have a beneficial effect on L-type Ca^2+^ channels but not on P/Q-type, N-type and T-type Ca^2+^ channels.

However, verapamil, as a small conductance calcium-activated potassium channels (SK channel) antagonist ([@B128]), may have a dual effect: improve memory but fail to have a neuroprotective role in AD ([@B59]).

Besides its general action as inhibitor of the transmembrane influx of extracellular calcium ions, verapamil, in several brain regions (e.g. cerebral cortex, hippocampus, hypothalamus), acts as an antagonist of muscarinic ([@B8]; [@B92]), α- and β-adrenergic ([@B33]; [@B124]; [@B126]), dopaminergic ([@B121]), serotoninergic ([@B130]; [@B2]; [@B37]; [@B93]; [@B117]), and GABAergic receptors ([@B125]). Thus, it is likely from these findings and the impairments of cholinergic ([@B39]), GABAergic ([@B62]), and monoaminergic transmission ([@B120]) in AD disease that verapamil could modify the neurotransmission in AD.

P-glycoprotein is a transmembrane glycoprotein localized in several barriers (e.g. blood-brain barrier (BBB), blood-cerebrospinal fluid barrier (BCSFB)). Its presence on the luminal membrane of the endothelial cells at the BBB ([@B9]), restricts the entry of an exogenous compound (e.g., drugs, xenobiotics, toxins) into the brain and also regulates the cellular efflux from the brain. Most of the studies support that P-glycoprotein is important for Aβ~1--40~ and Aβ~1--42~ clearance, and that dysfunction of this process might lead to AD development ([@B58]; [@B137]; [@B138]; [@B19]; [@B53]; [@B119]). Furthermore, microglia activation and, consequently, secretion of pro-inflammatory cytokines can disturb the P-glycoprotein production and function. On one hand, verapamil as P-glycoprotien inhibitor ([@B10]) may diminish the efflux of Aβ~1--40~ and Aβ~1--42~, while, on the other hand, it may restrain the pro-inflammatory processes and permit the entrance of some beneficial drugs, too.

During normal aging, there is a progressive decline in the BBB P-glycoprotein activity, particularly in men but not in women, that can lead to the accumulation of harmful compounds in the brain parenchyma ([@B7]; [@B134]). Furthermore, the decreased BBB P-glycoprotein function in young women, compared with young men, may implicate an increased risk of AD in women ([@B134]). Nowadays, R-\[^11^C\]verapamil isomer is being used for the evaluation of the blood-brain barrier function in aging and AD, since its high uptake as radiotracer indicates decreased P-glycoprotein functionality in these conditions ([@B67]; [@B135]; [@B17]).

Intriguingly, low and high systolic blood pressure trajectories from mid- to late-life have been associated with cognitive deficit and increased risk of AD ([@B122]; [@B50]; [@B102]; [@B73]). The daily fluctuations of blood pressure highlight the importance of synchronizing antihypertensive therapy with time of day ([@B42]; [@B43]). Similarly, the half-life of verapamil during the evening dosing regimen is much longer than the morning treatment ([@B46]). Bearing in mind that intracellular Ca^2+^ oscillates on a circadian and ultradian rhythm base ([@B83]; [@B143]) and that circadian rhythm is highly disturbed in AD patients ([@B21]) a chronotherapy with verapamil in AD patents should be considered.

Finally, since the age and gender may modify the verapamil pharmacokinetic and pharmacodynamic effect on a stereoselective (S- and R-isomers) base ([@B113]; [@B109]; [@B111]; [@B112]; [@B38]; [@B114]; [@B51]; [@B22]), it seems reasonable to consider the [@B30] proposal, which suggests testing the efficacy of S- and R-verapamil molecules in AD models separately.

Conclusion {#s3}
==========

Experimental data in animal models of AD indicated a potential positive effect of verapamil in ameliorating AD-like pathology. However, the lack of clinical findings limits its potential use in AD therapy. Probably, instead of a racemic mixture of both isomers, the equilibrate percent of each isomer should be considered. Moreover, the dose used, daytime therapy schedule, and route of verapamil application should be adjusted depending on individual conditions (gender, age, the severity of AD pathology, person's chronotype, etc). Multimorbidity increases with aging and most of the AD patients are on polypharmacotherapy. Therefore, a possible interaction between verapamil and other drugs needs to be considered. Bearing in mind that presently, more than eight million people, just in the USA, are currently on verapamil treatment, it would seem that a rational approach to personalized AD therapy will not only be beneficial for patients, but it will also decrease the harmful impact of verapamil on the environment ([@B108]) and health economics.
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